Why the study?
Differences in efficacy and safety outcomes between bivalirudin and unfractionated heparin in patients with cardiogenic shock requiring VA ECMO needed evaluation.
Does bivalirudin reduce ECMO-associated thrombotic events and major bleeding compared to unfractionated heparin in patients with cardiogenic shock requiring VA ECMO?
Population
143 patients >18 years of age supported with VA ECMO for cardiogenic shock
Comparison
Bivalirudin vs unfractionated heparin
Design
Single-center retrospective study
Authors
Loading...
May support bivalirudin over UFH in VA ECMO; leaves open confirmation in randomized trials.
Does bivalirudin reduce ECMO-associated thrombotic events and major bleeding compared to unfractionated heparin in patients with cardiogenic shock requiring VA ECMO?
In patients requiring VA ECMO for cardiogenic shock, bivalirudin is associated with fewer thrombotic and major bleeding events compared to unfractionated heparin.
Uricchio et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: